Havrix 720 Junior/Havrix 1440 Adult

Havrix 720 Junior/Havrix 1440 Adult

vaccine, hepatitis a

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
HAV vaccine (inactivated, adsorbed)
Indications/Uses
Active immunisation against HAV infection in subjects at risk of exposure to HAV.
Dosage/Direction for Use
IM inj Primary immunisation: Adult ≥19 yr A single dose of Havrix 1440 Adult. Childn & adolescent 1-18 yr A single dose of Havrix 720 Junior. A booster dose is recommended between 6 & 12 mth after the 1st dose of Havrix 1440 Adult or Havrix 720 Junior in order to ensure long-term protection.
Special Precautions
Acute severe febrile illness (postpone vaccination), impaired immune system or those on haemodialysis may require additional doses. Thrombocytopenia or bleeding disorder. Do not administer IV, SC or intradermally. Do not administer in gluteal region. Anaphylactic events following administration. Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle inj. Pregnancy & lactation.
Adverse Reactions
Inj site pain, redness & swelling, drowsiness, GI symptoms, fatigue, irritability, headache, malaise, vomiting, fever (≥37.5°C), nausea & loss of appetite.
Drug Interactions
When in concomitant administration of other vaccines or of Ig is considered necessary, the products must be given w/ different syringes & needles, & at different inj sites.
ATC Classification
J07BC02 - hepatitis A, inactivated, whole virus ; Belongs to the class of hepatitis viral vaccines.
Presentation/Packing
Form
Havrix 720 Junior vaccine inj 720 ELISA u/0.5 mL
Packing/Price
1's
Form
Havrix 1440 Adult vaccine inj 1440 ELISA u/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in